[Skip to Content]
[Skip to Content Landing]
Article
April 1990

The Ocular Hypotensive Effect of the Topical Carbonic Anhydrase Inhibitor L-671,152 in Glaucomatous Monkeys

Author Affiliations

From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Wang, Serle, and Podos), and Merck Sharp and Dohme, West Point, Pa (Dr Sugrue).

Arch Ophthalmol. 1990;108(4):511-513. doi:10.1001/archopht.1990.01070060059049
Abstract

• L-671,152, a new potent water-soluble inhibitor of human carbonic anhydrase II in vitro, was applied topically to cynomolgus monkey eyes in which glaucoma had been produced by argon laser photocoagulation of the trabecular meshwork. Intraocular pressure was measured at 0 hours, 0.5 hours, and hourly for 8 hours in eight eyes for 2 baseline days, 1 day receiving the vehicle and 5 days receiving therapy with 2% L-671, 152 twice a day, after initial single-dose trials of various concentrations. Intraocular pressure was not significantly different comparing baseline and vehicle-treated days. Significant intraocular pressure reductions occurred from 1 to 8 hours after the first dose, and lasted for at least 16 hours after the second dose. The reduction in intraocular pressure became more pronounced from day 1 to day 5 at each time interval. The mean (± SEM) maximum reduction in intraocular pressure was 7.8 ± 2.1 mm Hg on day 1 and 10.1 ± 2.4 mm Hg on day 5 at 3 hours after administration, comparing the intraocular pressure in drug-treated and vehicle-treated eyes. L-671,152 has a longer duration of action than does previously studied MK-927 in glaucomatous monkeys. It appears to have great clinical potential.

×